title: High SEPT9_i1 protein expression is associated with high-grade prostate cancers.
abstract: Septins are a family of GTP-binding cytoskeleton proteins expressed in many solid tumors. Septin 9 (SEPT9) in particular was found overexpressed in diverse carcinomas. Herein, we studied the expression of SEPT9 isoform 1 protein (SEPT9_i1) in human prostate cancer specimens. We utilized immunohistochemical staining to study the expression of SEPT9_i1 protein. Staining level was analyzed in association with clinical characteristics and the pathological Gleason grade and score. Fifty human prostate cancer specimens (42 primary tumors and 8 metastatic lesions) were stained by SEPT9_i1 antibody and analyzed. SEPT9_i1 protein was expressed in prostate cancer cells but absent in normal epithelial cells. The intensity of staining was correlated proportionally to pretreatment prostate-specific antigen (PSA) blood levels and Gleason score (P < 0.05). SEPT9_i1 was highly expressed in all metastatic lesions. A significant assocation between SEPT9_i1 expression and high Gleason score on multivariate linear regression analysis was found. We conclude that SEPT9_i1 is expressed in high-grade prostate tumors suggesting it has a significant role in prostate tumorigenesis and that it could serve as a molecular marker for prostate tumor progression.
authors.affiliation: Department of Urology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Roni
authors.initials: R
authors.lastname: Gilad
authors.affiliation: Department of Pathology, The Hebrew University-Hadassah Medical School, Jerusalem, Israel.
authors.forename: Karen
authors.initials: K
authors.lastname: Meir
authors.affiliation: Department of Pathology, The Hebrew University-Hadassah Medical School, Jerusalem, Israel.
authors.forename: Ilan
authors.initials: I
authors.lastname: Stein
authors.affiliation: Department of Urology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Larissa
authors.initials: L
authors.lastname: German
authors.affiliation: Department of Pathology, The Hebrew University-Hadassah Medical School, Jerusalem, Israel.
authors.forename: Eli
authors.initials: E
authors.lastname: Pikarsky
authors.affiliation: Department of Urology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Nicola J
authors.initials: NJ
authors.lastname: Mabjeesh
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology* / Q000556:secondary; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001859:Bone Neoplasms / Q000201:enzymology* / Q000556:secondary; D018450:Disease Progression; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D011471:Prostatic Neoplasms / Q000201:enzymology* / Q000473:pathology; D012189:Retrospective Studies; D058112:Septins / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; D007527:Isoenzymes; C474315:SEPTIN9 protein, human; D058112:Septins